Eva Yin will be presenting at Rice Alliance and BioHouston's 13th Annual Texas Life Science Forum on November 7, 2024 on FDA & Healthcare Regulatory Considerations for Startups in Biotech & Medtech. This session provides an overview of key FDA and healthcare regulatory considerations for startups in the life sciences space as well as recent developments impacting the biotech and medtech industries.
Wilson Sonsini is proud to support the Texas Life Science Forum, a premier life science and healthtech event in Texas that brings together members from industry, emerging life science companies, academic and investors.
Chrystel Gelin
cgelin@wsgr.comEva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.